<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697617</url>
  </required_header>
  <id_info>
    <org_study_id>IndianaU 1308084213</org_study_id>
    <secondary_id>FD-R-004826-01-A2</secondary_id>
    <nct_id>NCT02697617</nct_id>
  </id_info>
  <brief_title>Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease</brief_title>
  <acronym>PIOPKD</acronym>
  <official_title>Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Funding Source - FDA OOPD&#xD;
&#xD;
      Pioglitazone is currently used in clinical practice to treat diabetes and this study will&#xD;
      examine the potential use of a low dose of the same drug for the treatment of polycystic&#xD;
      kidney disease. The purpose of this study is to determine whether the diabetes drug&#xD;
      pioglitazone (Actos) is a safe and effective treatment of autosomal dominant polycystic&#xD;
      kidney disease when treated in its early stages. Pioglitazone is approved by the FDA for the&#xD;
      treatment of diabetes. Pre-clinical models of polycystic kidney disease have shown that low&#xD;
      dose treatment with pioglitazone decreases the growth of the cysts. The studies also suggest&#xD;
      that effective pioglitazone dosing for polycystic kidney disease may be lower than that used&#xD;
      to treat diabetes. The purpose of this study is to see if pioglitazone might slow cyst&#xD;
      disease in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomize to placebo or 15 mg pioglitazone for 12 months, and then be&#xD;
      crossed over to the other arm. Patients will undergo MRI of the liver and kidney and&#xD;
      MRspectroscopy of the lumbar spine (if they choose as this is ancillary study) three times&#xD;
      during the study. Assessments will be every 3 months and include blood work, blood pressure,&#xD;
      and body water assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 26, 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Total Body Water</measure>
    <time_frame>average of 4 measures in each 12 month arm</time_frame>
    <description>Bioimpedance analysis (BIA)(Ohms); Increase in BIA in Ohms indicates a decrease in total body water</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Percent Change in Total Kidney Volume</measure>
    <time_frame>Baseline, end of year 1, and end of year 2</time_frame>
    <description>Change in total kidney volume by Magnetic Resonance Imaging (MRI) from beginning to end of the 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Hypoglycemia</measure>
    <time_frame>measured quarterly for 12 months in pioglitazone and same in placebo</time_frame>
    <description>number of patients with blood sugar &lt; 70 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Elevated Liver Function Tests</measure>
    <time_frame>measured quarterly over 12 months for each arm</time_frame>
    <description>Number of patients with elevated liver test (ALT or AST) &gt; 2 times upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Glomerular Filtration Rate</measure>
    <time_frame>average of 4 values over 12 months</time_frame>
    <description>average estimated glomerular filtration rate by chronic kidney disease (CKD) epidemiologic (epi) formula measured quarterly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Blood Pressure</measure>
    <time_frame>average of 4 measures over 12 months</time_frame>
    <description>mean systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Marrow Fat</measure>
    <time_frame>Baseline, end of year 1, and end of year 2</time_frame>
    <description>We will assess change in bone marrow fat by MR spectroscopy as an ancillary study to be done at the same time as MRI; will not be done due to person leaving institution.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be on placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will be on pioglitazone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone</description>
    <arm_group_label>Pioglitazone Arm</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with autosomal dominant polycystic kidney disease (ADPKD) aged&#xD;
             18-55&#xD;
&#xD;
          -  estimate glomerular filtration rate (GFR) at or above â‰¥ 50 ml/min/1.73 m2 by any GFR&#xD;
             formula&#xD;
&#xD;
          -  Normal liver enzymes (ALT/AST)&#xD;
&#xD;
          -  fasting blood glucose between 70 and120&#xD;
&#xD;
          -  for female patients, a willingness to use double contraception to avoid pregnancy&#xD;
             while in study&#xD;
&#xD;
          -  able to give informed consent&#xD;
&#xD;
          -  In the opinion of the investigator, high likelihood of progressive kidney disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetes, defined as any of the following: fasting blood sugar &gt; 130 times two, HgbA1C&#xD;
             &gt; 7, on any blood sugar lowering medication, or past diagnosis of diabetes not&#xD;
             occurring during pregnancy&#xD;
&#xD;
          -  uncontrolled hypertension as determined by the examining physician&#xD;
&#xD;
          -  history of impaired systolic function (ejection fraction &lt; 50%) by previous&#xD;
             echocardiogram or known ischemic cardiovascular disease&#xD;
&#xD;
          -  findings suggestive of a kidney disease other than ADPKD&#xD;
&#xD;
          -  systemic illness requiring immunosuppressive or anti-inflammatory agents&#xD;
&#xD;
          -  congenital absence of a kidney or history of a total nephrectomy&#xD;
&#xD;
          -  history of cyst reduction or partial nephrectomy&#xD;
&#xD;
          -  history of renal cyst aspiration within the previous year&#xD;
&#xD;
          -  History of bladder cancer, or gross hematuria&#xD;
&#xD;
          -  inability to undergo MRI due to implantable devices or foreign objects that preclude&#xD;
             MRI&#xD;
&#xD;
          -  active renal transplant&#xD;
&#xD;
          -  allergy or sensitivity to any of the components of the test materials&#xD;
&#xD;
          -  institutionalized&#xD;
&#xD;
          -  currently pregnant or plans to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Moe, 317-944-7580</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <results_first_submitted>October 19, 2020</results_first_submitted>
  <results_first_submitted_qc>December 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2021</results_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Sharon Moe</investigator_full_name>
    <investigator_title>MD, Stuart A. Kleit Professor of Medicine, Director, Division of Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02697617/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02697617/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Age 18-55 years old, with known autosomal dominant polycystic kidney disease (ADPKD), estimated glomerular filtration rate (eGFR) &gt; 50 ml/min/m2 on recent labs, and no history of diabetes were identified using international disease codes (ICD-9) code for cystic kidney disease by search of electronic medical records or through advertisements and letters sent to Nephrologists.</recruitment_details>
      <pre_assignment_details>Patients who fulfilled the initial screening underwent further screening with a baseline magnetic resonance imaging (MRI) and randomized to pioglitazone or placebo providing the total kidney volume (TKV) was â‰¥675 ml (18-25 years old), â‰¥ 900 ml (26-35 years old), and â‰¥ 1350 ml (36-55 years old).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PIO Then PLACEBO</title>
          <description>Sequence Pioglitazone then Placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then PIO</title>
          <description>sequence placebo then pioglitazone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8">15 completed both arms</participants>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>18 patients randomized to either pioglitazone for 12 months and then placebo for 12 months and then cross over to the other arm. So baseline data represents both arms</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>at randomization to sequence 1 (pioglitazone 15 mg) or placebo for cross over study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>estimated glomerular filtration rate (eGFR) by CKD-epi</title>
          <units>ml/min/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>right kidney volume</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="965" spread="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>left kidney volume</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1078" spread="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Total Body Water</title>
        <description>Bioimpedance analysis (BIA)(Ohms); Increase in BIA in Ohms indicates a decrease in total body water</description>
        <time_frame>average of 4 measures in each 12 month arm</time_frame>
        <population>All patients randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Total body water</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Total Body Water</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Total Body Water</title>
          <description>Bioimpedance analysis (BIA)(Ohms); Increase in BIA in Ohms indicates a decrease in total body water</description>
          <population>All patients randomized</population>
          <units>Ohms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.78" lower_limit="39.19" upper_limit="52.36"/>
                    <measurement group_id="O2" value="44.17" lower_limit="37.96" upper_limit="50.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>First analyzed using a Linear Mixed Model to assess if there were carryover effects and then subsequently analyzed using paired t-tests to compare the mean differences between treatments.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Percent Change in Total Kidney Volume</title>
        <description>Change in total kidney volume by Magnetic Resonance Imaging (MRI) from beginning to end of the 12 months</description>
        <time_frame>Baseline, end of year 1, and end of year 2</time_frame>
        <population>Those who completed both arms</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 15 mg Daily</title>
            <description>Patients who completed both arms, data from the 12 months of pioglitazone treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo po Daily</title>
            <description>of patients who finished both arms, the results from the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percent Change in Total Kidney Volume</title>
          <description>Change in total kidney volume by Magnetic Resonance Imaging (MRI) from beginning to end of the 12 months</description>
          <population>Those who completed both arms</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" lower_limit="0.84" upper_limit="7.86"/>
                    <measurement group_id="O2" value="7.85" lower_limit="3.6" upper_limit="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>First analyzed using a Linear Mixed Model to assess if there were carryover effects and then subsequently analyzed using paired t-tests to compare the mean differences between treatments.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Hypoglycemia</title>
        <description>number of patients with blood sugar &lt; 70 mg/dl</description>
        <time_frame>measured quarterly for 12 months in pioglitazone and same in placebo</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 15 mg</title>
            <description>All patients taking pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>all patients taking placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Hypoglycemia</title>
          <description>number of patients with blood sugar &lt; 70 mg/dl</description>
          <population>All randomized participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Elevated Liver Function Tests</title>
        <description>Number of patients with elevated liver test (ALT or AST) &gt; 2 times upper limit of normal</description>
        <time_frame>measured quarterly over 12 months for each arm</time_frame>
        <population>All patients who were randomized, regardless of whether they completed both arms</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 15 mg</title>
            <description>All patients taking pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>all patients taking placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Elevated Liver Function Tests</title>
          <description>Number of patients with elevated liver test (ALT or AST) &gt; 2 times upper limit of normal</description>
          <population>All patients who were randomized, regardless of whether they completed both arms</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>comparison by paired t-test</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Glomerular Filtration Rate</title>
        <description>average estimated glomerular filtration rate by chronic kidney disease (CKD) epidemiologic (epi) formula measured quarterly</description>
        <time_frame>average of 4 values over 12 months</time_frame>
        <population>All patients that completed both arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 15 mg</title>
            <description>All patients taking pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>all patients taking placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Glomerular Filtration Rate</title>
          <description>average estimated glomerular filtration rate by chronic kidney disease (CKD) epidemiologic (epi) formula measured quarterly</description>
          <population>All patients that completed both arms.</population>
          <units>ml/min/m2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="62" upper_limit="89"/>
                    <measurement group_id="O2" value="78.1" lower_limit="64" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>First analyzed using a Linear Mixed Model to assess if there were carryover effects and then subsequently analyzed using paired t-tests to compare the mean differences between treatments.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Blood Pressure</title>
        <description>mean systolic and diastolic blood pressure</description>
        <time_frame>average of 4 measures over 12 months</time_frame>
        <population>All patients that completed both arms</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 15 mg</title>
            <description>All patients taking pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>all patients taking placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Blood Pressure</title>
          <description>mean systolic and diastolic blood pressure</description>
          <population>All patients that completed both arms</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" lower_limit="124" upper_limit="130"/>
                    <measurement group_id="O2" value="129" lower_limit="124" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="81" upper_limit="86"/>
                    <measurement group_id="O2" value="82" lower_limit="82" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <p_value_desc>First analyzed using a Linear Mixed Model to assess if there were carryover effects and then subsequently analyzed using paired t-tests to compare the mean differences between treatments.</p_value_desc>
            <method>paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Marrow Fat</title>
        <description>We will assess change in bone marrow fat by MR spectroscopy as an ancillary study to be done at the same time as MRI; will not be done due to person leaving institution.</description>
        <time_frame>Baseline, end of year 1, and end of year 2</time_frame>
        <population>The MRIs were done, but could not be analyzed as requires special expertise and software.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 15 mg Daily</title>
            <description>Patients who completed both arms, data from the 12 months of pioglitazone treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo po Daily</title>
            <description>of patients who finished both arms, the results from the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Marrow Fat</title>
          <description>We will assess change in bone marrow fat by MR spectroscopy as an ancillary study to be done at the same time as MRI; will not be done due to person leaving institution.</description>
          <population>The MRIs were done, but could not be analyzed as requires special expertise and software.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>15 mg po daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Over encapsulated (identical appearing) placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>surgery</sub_title>
                <description>elective surgery/gastric banding</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>pancreatitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal symptom</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection or pain</sub_title>
                <description>or cyst rupture</description>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="18" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E2" events="30" subjects_affected="15" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="23" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The major limitation is the small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sharon Moe</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>317 278 2868</phone>
      <email>smoe@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

